Last Updated on October 17, 2024 by The Health Master
Lupin, an innovation-led transnational pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), pregabalin capsules.
Pregabalin capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg to market a generic equivalent of Lyrica capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of Upjohn US 2 LLC.
The product will be manufactured at Lupin’s facility in Aurangabad, India.
Pregabalin capsules (Lyrica) had estimated annual sales of USD 263 million in the US (IQVIA MAT March 2022).
USFDA gives final approval to Aleor Dermaceuticals for Docosanol cream
USFDA gives nod to these companies for Bortezomib for injection
USFDA grants approval for drug to treat spondylitis
USFDA approves this oral heart disease drug
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
USFDA gives nod to Lupin for Desvenlafaxine ER tablets
Global drug development centre set up for APIs and Formulations
New molecule discovered that can be used for treatment of diabetes
USFDA gives final approval to Aleor Dermaceuticals for Docosanol cream
Pharma Sector: “Act as if every day is an Audit”
USFDA gives nod to these companies for Bortezomib for injection
Israel opens world’s most protected Blood Bank
USFDA grants approval for drug to treat spondylitis
A smarter way to develop new drugs
DCGI extends timeline for Pharma Firms to regularize 294 FDCs
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
